Skip to main content
Home > SciBX > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Positioning properdin

    Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. The researchers are…

    Published on 4/10/2014
  • Narrowing down graft stenosis

    One serious complication after coronary artery bypass graft surgery is hyperplastic growth of the transplant. Now, a U.S. team has reported that this hyperplasia is rooted in the endothelial cells lining the …

    Published on 4/3/2014
  • Insights into ependymoma

    Two independent studies have revealed targets for previously intractable ependymoma tumors: a fusion protein and epigenetic modifiers, respectively. The therapeutic potential of the targets remains to be established.

    Published on 3/27/2014
  • Zinc-ing about diabetes

    ZNT8 burst onto the scene in 2007 as a promising diabetes target, and follow-up studies suggested that stimulating the zinc transporter protein could have therapeutic benefit. A new study suggests that the preferred …

    Published on 3/13/2014
  • Table 1: Cardiovascular expressions

    Targets & Mechanisms: Heart cells: no longer undivided Table 1. Cardiovascular expressions. At least 10 companies have gene therapies in preclinical through Phase III development to treat a range of cardiovascular …

    Published on 3/6/2014
  • Depending on SWI/SNF

    Loss-of-function mutations in chromatin-modifying proteins remain largely intractable. Separate teams, including a group from Novartis, have identified synthetic lethal interactions that could be exploited to help treat…

    Published on 3/6/2014
  • Heart cells: no longer undivided

    The inability of heart cells to divide rapidly enough to repair damage is a major impediment to regenerating heart tissue after myocardial infarction. A U.S. team has used cyclin A2 gene therapy to induce cardiomyocyte …

    Published on 3/6/2014
  • The XII factor

    Researchers have found that inhibiting either factor XII or factor XI can provide thromboprotection without increasing the risk of bleeding. Both targets could eliminate the main drawback of existing anticoagulants.

    Published on 2/27/2014
  • Table 1: Targeting the intrinsic pathway of coagulation and the kallikrein-kinin system

    The XII factor Table 1. Targeting the intrinsic pathway of coagulation and the kallikrein-kinin system. The intrinsic pathway and the kallikrein-kinin system are both activated by factor XIIa. The table below is a …

    Published on 2/27/2014
  • Figure 1: Factor XIIa pathways

    Targets & Mechanisms: The XII factor Figure 1. Factor XIIa pathways. The intrinsic pathway of coagulation and the kallikrein-kinin system are both activated downstream of factor XII (FXII). (I) In the intrinsic …

    Published on 2/27/2014
  • Preserving the oocyte reserve

    A Cornell team has preserved fertility in mice by knocking out checkpoint kinase 2. The target offers companies a new opportunity for preventing chemotherapy- and radiotherapy-induced premature menopause and infertility…

    Published on 2/20/2014
  • A RIPping target in Gaucher's disease

    Enzyme-replacement therapies are highly effective for most patients with Gaucher's disease but do little for those with the neuronopathic childhood forms of the disease. Now, an Israeli and U.K. team has unlocked the …

    Published on 2/13/2014
  • Table 1: Gaucher's disease pipeline

    Targets & Mechanisms: A RIPping target in Gaucher's disease Table 1. Gaucher's disease pipeline. Selected compounds on the market or in clinical development for Type I Gaucher's disease. Source: BCIQ: BioCentury …

    Published on 2/13/2014
  • Figure 1: PCSK9-mediated regulation of LDLR levels

    PCSK9 peptide inhibitors Figure 1. PCSK9-mediated regulation of LDLR levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) is highly expressed in the liver and is a validated target for hypercholesterolemia. …

    Published on 2/6/2014
  • Negative nanoparticles

    Simple experimental error has opened up the potential for nanoparticles to treat disease rather than be used as payloads. By accidentally using negatively charged nanoparticles instead of neutral ones, a team from …

    Published on 2/6/2014
  • PCSK9 peptide inhibitors

    Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the …

    Published on 2/6/2014
  • PTSD: rewriting fearful memories

    An MIT-led team has outlined a strategy for addressing the underlying causes of post-traumatic stress disorder. The approach centers on blocking HDAC2, which is the only class I histone deacetylase target shown to play …

    Published on 1/30/2014
  • Melanoma checkpoint inhibitors

    U.S. researchers have found that a cocktail of antibodies targeting checkpoint proteins and peptide-based cancer vaccines induced a potent and tumor-specific T cell response to treat melanoma.

    Published on 1/16/2014
  • Putting a lid on cancer cell proteasomes

    A Johns Hopkins University team has discovered a compound, RA190, which suppresses tumor growth by blocking the regulatory subunit of proteasomes. The team is now working on enhancing the compound's drug-like properties…

    Published on 1/16/2014
  • Covalent hits on KRAS

    UCSF- and Harvard Medical School-led teams have independently synthesized the first covalent inhibitors of a common oncogenic form of KRAS. Araxes has licensed the UCSF team's findings and has partnered with Johnson & …

    Published on 1/9/2014
  • The next battle line against melanoma

    Boston and Los Angeles researchers have reported mechanisms of resistance to BRAF and MEK inhibitors in melanoma. The work points to targets downstream of BRAF that could lead to combination therapies to forestall …

    Published on 1/9/2014
  • Balancing act in liver fibrosis

    U.S. researchers have shown that CXCR7 and CXCR4 play proregenerative and profibrotic roles following liver injury, making the proteins therapeutic targets to prevent or treat liver fibrosis.

    Published on 12/19/2013
  • Lipid kinase enters the malaria stage

    A Novartis-UCSD-led consortium has identified a new class of antimalarials that, unlike marketed drugs, eliminates Plasmodium at all stages of its infection cycle. The pharma is developing derivatives of the lead …

    Published on 12/19/2013
  • ClpPing persistence

    Northeastern University researchers have combined traditional antibiotics with compounds that activate bacterial clpP protease and cured mice with severe, highly drug-resistant Staphylococcus biofilm infections. Arietis…

    Published on 12/12/2013
  • Figure 1: The commensal bacteria-butyrate-Treg cell axis of inflammatory regulation in the gut

    Targets & Mechanisms: A gut feeling about butyrate Figure 1. The commensal bacteria-butyrate-Treg cell axis of inflammatory regulation in the gut. Certain commensal bacteria abundantly produce butyrate through …

    Published on 12/5/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993